High-Dose Interleukin-2: Evaluation of a Standardized Order Set for Biotherapy in an Intensive Care Unit .
BACKGROUND
Life-threatening toxicity may result from administration of high-dose (HD) interleukin-2 (IL-2). Patients receiving HD IL-2 treatment often experience severe adverse side effects, which result in the interruption of treatment.  .


OBJECTIVE
A standardized order set (SOS) was developed for patients with melanoma or renal cell carcinoma receiving HD IL-2. The aims of the study were to determine compliance of clinicians to the SOS, report the completed doses and major side effects of HD IL-2, and document the satisfaction level of clinicians. .


METHODS
A retrospective chart review of 40 health records of patients with melanoma or renal cell carcinoma who were treated with HD IL-2 was conducted to determine compliance to the SOS. Staff satisfaction with the SOS was surveyed. .


RESULTS
The SOS was successfully implemented with a provider compliance rate of 90%. Cardiovascular side effects were the most common. Clinicians found the SOS very satisfactory or superior in guiding care and treatment of side effects.
University of California, San Francisco (UCSF) Medical Center.
Rusticio
R
Portillas
Duke University.
Barbara
B
Turner
UCSF Medical Center at Mission Bay.
Audrey
A
Jeffers
University of California, San Francisco (UCSF) Medical Center.
Lee-Lynn
LL
Chen
Duke University.
Mary
M
Champagne
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D011307:Drug Prescriptions / Q000592:standards*; D005260:Female; D006801:Humans; D007362:Intensive Care Units / Q000592:standards; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D007376:Interleukin-2
high-dose interleukin-2; metastatic melanoma; renal cell carcinoma; toxicity 